Stopping Anti-TNF Agents in Patients with Crohn's Disease in Remission: Is It a Feasible Long-term Strategy?

被引：22

作者：

Sorrentino, Dario ^{[1
,2
,3
]}

Nash, Peter ^{[4
]}

Viladomiu, Monica ^{[2
]}

Hontecillas, Raquel ^{[2
]}

Bassaganya-Riera, Josep ^{[2
]}

机构：

[1] Virginia Tech, Div Gastroenterol, IBD Ctr, Caril Sch Med, Roanoke, VA 24016 USA

[2] Virginia Tech, Nutr Immunol & Mol Med Lab, Virginia Bioinformat Inst, Blacksburg, VA USA

[3] Univ Udine, Sch Med, Dept Clin & Expt Med Sci, I-33100 Udine, Italy

[4] Univ Queensland, Dept Med, Brisbane, Qld 4000, Australia

来源：

INFLAMMATORY BOWEL DISEASES | 2014年 / 20卷 / 04期

关键词：

anti-TNF agents; Crohn's disease; long term therapy; stopping biologics; immunomodulators; INFLAMMATORY-BOWEL-DISEASE; ANTITUMOR NECROSIS FACTOR; REGULATORY T-CELLS; RHEUMATISM PROVISIONAL DEFINITION; LOW-DOSE INFLIXIMAB; FOLLOW-UP; RHEUMATOLOGY/EUROPEAN LEAGUE; POSTOPERATIVE RECURRENCE; CLINICAL REMISSION; AMERICAN-COLLEGE;

D O I：

10.1097/01.MIB.0000442680.47427.bf

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：757 / 766

页数：10

共 69 条

[31]

Holtta Veera, 2012, ISRN Gastroenterol, V2012, P505432, DOI 10.5402/2012/505432

[32] Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease [J].

Itoh, J ;

de la Motte, C ;

Strong, SA ;

Levine, AD ;

Fiocchi, C .

GUT, 2001, 49 (01) :35-41

[33] Low-dose infliximab treatment for ankylosing spondylitis- clinically- and cost-effective [J].

Jois, R. N. ;

Leeder, J. ;

Gibb, A. ;

Gaffney, K. ;

Macgregor, A. ;

Somerville, M. ;

Scott, D. G. I. .

RHEUMATOLOGY, 2006, 45 (12) :1566-1569

[34] Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response [J].

Lichtenstein, Gary R. .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2013, 6 (04) :269-293

[35] Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease [J].

Liu, C. ;

Xia, X. ;

Wu, W. ;

Wu, R. ;

Tang, M. ;

Chen, T. ;

Xu, F. ;

Cong, Y. ;

Xu, X. ;

Liu, Z. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 173 (01) :102-111

[36] Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped [J].

Louis, Edouard ;

Mary, Jean-Yves ;

Vernier-Massouille, Gwenola ;

Grimaud, Jean-Charles ;

Bouhnik, Yoram ;

Laharie, David ;

Dupas, Jean-Louis ;

Pillant, Helene ;

Picon, Laurence ;

Veyrac, Michel ;

Flamant, Mathurin ;

Savoye, Guillaume ;

Jian, Raymond ;

Devos, Martine ;

Porcher, Raphael ;

Paintaud, Gilles ;

Piver, Eric ;

Colombel, Jean-Frederic ;

Lemann, Marc .

GASTROENTEROLOGY, 2012, 142 (01) :63-U201

[37] Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease [J].

McLeod, RS ;

Wolff, BG ;

Steinhart, AH ;

Carryer, PW ;

ORourke, K ;

Andrews, DF ;

Blair, JE ;

Cangemi, JR ;

Cohen, Z ;

Cullen, JB ;

Chaytor, RG ;

Greenberg, GR ;

Jaffer, NM ;

Jeejeebhoy, KN ;

MacCarty, RL ;

Ready, RL ;

Weiland, LH .

GASTROENTEROLOGY, 1997, 113 (06) :1823-1827

[38] Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy [J].

Molnar, T. ;

Lakatos, P. L. ;

Farkas, K. ;

Nagy, F. ;

Szepes, Z. ;

Miheller, P. ;

Horvath, G. ;

Papp, M. ;

Palatka, K. ;

Nyari, T. ;

Balint, A. ;

Lorinczy, K. ;

Wittmann, T. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (02) :225-233

[39] DISEASE-ACTIVITY COURSES IN A REGIONAL COHORT OF CROHNS-DISEASE PATIENTS [J].

MUNKHOLM, P ;

LANGHOLZ, E ;

DAVIDSEN, M ;

BINDER, V .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1995, 30 (07) :699-706

[40] Tumour necrosis factor inhibitors [J].

Nash, PT ;

Florin, THJ .

MEDICAL JOURNAL OF AUSTRALIA, 2005, 183 (04) :205-208

← 1 2 3 4 5 6 7 →